Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Molecular basis for improved anthrax vaccines.

Robert N Brey1

  • 1DOR BioPharma, Inc., 1691 Michigan Avenue, Suite 435, Miami, FL 33139, USA. rbrey@dorbiopharma.com

Advanced Drug Delivery Reviews
|June 7, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Binding of the von Willebrand Factor A Domain of Capillary Morphogenesis Protein 2 to Anthrax Protective Antigen Vaccine Reduces Immunogenicity in Mice.

mSphere·2020
Same author

Seneca Valley Virus Exploits TEM8, a Collagen Receptor Implicated in Tumor Growth.

Frontiers in oncology·2018
Same author

Recent advances in the development of vaccines against ricin.

Human vaccines & immunotherapeutics·2016
Same author

Clinical and Pathological Findings Associated with Aerosol Exposure of Macaques to Ricin Toxin.

Toxins·2015
Same author

Thermostable ricin vaccine protects rhesus macaques against aerosolized ricin: Epitope-specific neutralizing antibodies correlate with protection.

Proceedings of the National Academy of Sciences of the United States of America·2015
Same author

Combination of two candidate subunit vaccine antigens elicits protective immunity to ricin and anthrax toxin in mice.

Vaccine·2014
Same journal

Silicone oil in protein drug products and its implications for formulation stability.

Advanced drug delivery reviews·2026
Same journal

Targeted delivery of proteolysis-targeting chimeras (PROTAC) and molecular glue degraders (MGD).

Advanced drug delivery reviews·2026
Same journal

Lysosome-targeting degrader delivery system: from formulation design to biomedical applications.

Advanced drug delivery reviews·2026
Same journal

Anti-PEG antibodies in nanomedicine: Mechanisms, risks, and opportunities.

Advanced drug delivery reviews·2026
Same journal

Optimizing macrophage-targeted intracellular delivery systems for safe and effective immunotherapies.

Advanced drug delivery reviews·2026
Same journal

Light-controlled CRISPR-dCas9 epigenome editing: advanced drug-delivery strategies and oncology applications.

Advanced drug delivery reviews·2026
See all related articles

The current anthrax vaccine (AVA) is safe but difficult to produce. Next-generation vaccines focus on protective antigen (PA) and other virulence factors for improved immunity against anthrax.

Area of Science:

  • Immunology
  • Microbiology
  • Vaccinology

Background:

  • The existing anthrax vaccine adsorbed (AVA) was licensed in 1970, based on 1950s human trials.
  • AVA is safe and effective but challenging to manufacture and causes reactogenicity.
  • Research focuses on next-generation vaccines due to AVA's limitations.

Purpose of the Study:

  • To review the development of second-generation anthrax vaccines.
  • To highlight the importance of antibodies to protective antigen (PA) for immunity.
  • To explore the role of other virulence factors in achieving complete protection.

Main Methods:

  • Literature review of anthrax vaccine research.
  • Analysis of the role of protective antigen (PA) in B. anthracis virulence.

Related Experiment Videos

  • Examination of immune responses to anthrax virulence factors.

    • Main Results:

    • Antibodies to protective antigen (PA) are crucial for neutralizing anthrax toxins (lethal toxin and edema toxin).
    • Sufficient antibody levels to PA are necessary for protective immunity.
    • Immunity can be induced by purified PA, spores, or DNA plasmids expressing PA.

    Conclusions:

    • Next-generation anthrax vaccines aim to elicit antibodies against PA to neutralize toxins.
    • Antibodies targeting additional virulence factors like the capsule may be essential for sterilizing immunity.
    • Future vaccines will leverage a deeper understanding of host-pathogen interactions and immune responses.